MedTrace Logo

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

NCT00768755 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2015-10-28

Study results available
· View outcomes & findings →

Summary

AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).

Conditions

  • Carcinoma, Non-Small Cell Lung

Interventions

DRUG

axitinib

5mg BID po up to max 10mg BID po

DRUG

axitinib

5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy

DRUG

chemotherapy

Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles

DRUG

axitinib

5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy

DRUG

chemotherapy

Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-03-31
Completion
2012-03-31

Countries

  • United States
  • Italy
  • Japan
  • Poland
  • Romania
  • Russia
  • Spain
  • Switzerland
  • Taiwan
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00768755 on ClinicalTrials.gov